ASBP Aspire BioPharma, Inc.
Company Analysis
Latest News
π΄ Aspire BioPharma is trading 5.35% down in pre-market amid broader risk-off trading
Aspire BioPharma is now trading 5.35% down in pre-market at $8.50, with the decline appearing aligned with broader risk-off trading and no fresh...
π’ Aspire BioPharma is trading 5% up today
Aspire BioPharma is trading 5% up at $8.95, with no fresh company-specific catalyst identified. - Shares rose from the August 28 close of $8.51. - No fresh...
π’ Aspire BioPharma is trading 5% up today
Aspire BioPharma is trading at $8.70, up +5.33% on August 28, 2026, after rising from the August 27 close of $8.26. - No clear company-specific announcement...
π΄ Aspire BioPharma is trading 6.24% down in after-hours trading β no verified company-specific catalyst identified
Aspire BioPharma is trading at $7.81 (-6.24%) in after-hours trading after no verified company-specific announcement or late-breaking catalyst was identified...
π’ Aspire BioPharma is trading 10.78% up today as XBI biotech ETF rises 2.06%
Aspire BioPharma is trading 10.78% up at $8.65, primarily on stronger biotech-sector sentiment. - No clear company-specific announcement or filing dated...
π’ Aspire BioPharma is trading 5.63% up today amid stronger biotech-sector sentiment
Aspire BioPharma is trading at $8.25, up 5.63%, amid stronger biotech-sector sentiment. - No clear August 25, 2026 company-specific announcement or filing...
π΄ Aspire BioPharma is trading 5% down in pre-market
Aspire BioPharma is trading 5.24% down at $7.55 after no clear company-specific catalyst was identified for August 24, 2026. - Completed the Dura Driver...
π’ Aspire BioPharma is trading 6.5% up today after new investor presentation and Sidoti conference
Aspire BioPharma is trading 6.5% up at $8.14 after filing a new investor presentation and presenting at the Sidoti Micro-Cap Virtual Investor Conference on...
Aspire Biopharma Holdings Files New Investor Presentation
Aspire Biopharma Holdings, Inc. filed a Form 8-K to announce the distribution of a new investor presentation, dated August 19, 2026. Key Details Filing...
Aspire BioPharma's Losses Shrink But Revenue Stays Tiny β Can a $7 Stock Justify the Optimism?
Shares jumped as investors digested second-quarter results showing Aspire BioPharma's cash burn is slowing dramatically, even as the company generates almost...
π’ Aspire BioPharma is trading 7.31% up today after reporting narrower second-quarter losses
Aspire BioPharma is trading at $7.63 (+7.31%) after reporting second-quarter results with a narrower net loss. - Second-quarter sales were $63,104, while net...
π΄ Aspire BioPharma is trading 5.9% down today β no clear company-specific catalyst identified
Aspire BioPharma is trading 5.9% down at $7.16, with no clear company-specific catalyst identified for the August 12, 2026 decline. - On August 10, the...
π΄ Aspire BioPharma is trading 5.26% down in pre-market β no clear company-specific catalyst identified
Aspire BioPharma is trading 5.26% down at $7.21 after no clear company-specific overnight catalyst was identified. - The latest major announcement was the...
π΄ Aspire BioPharma is trading 5.52% down today in pre-market with no clear company-specific catalyst identified
Aspire BioPharma is trading 5.52% down at $7.36 in pre-market, with no clear overnight negative company-specific catalyst identified. - It closed at $7.79 on...
Aspire BioPharma, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
Aspire BioPharma enters its Q2 2026 earnings report with minimal formal coverage, though historical run-rates suggest a consensus revenue of approximately...
π΄ Aspire BioPharma is trading 6.29% down today in after-hours trading; no catalyst confirmed
Aspire BioPharma is trading at $7.30, down 6.29%, with no separate after-hours catalyst confirmed. - Regular-session close was $7.79, following a 0.78%...
π΄ Aspire BioPharma is trading 5% down today β no separate catalyst confirmed
Aspire BioPharma is trading 5% down now at $7.33; no separate catalyst explaining the decline has been confirmed. - On August 10, 2026, the company announced...
π’ Aspire BioPharma is trading 10.20% up today amid biotech M&A optimism
Aspire BioPharma is trading $7.78 (+10.20%) as stronger biotech-sector sentiment appears linked to broader M&A optimism, though company-specific causation...
π’ Aspire BioPharma is trading 6.03% up today amid renewed biotech M&A speculation
Aspire BioPharma is trading 6.03% up now at $7.70, with the move appearing primarily linked to stronger biotech sentiment. - The sector ETF is up 2.09% during...
π’ Aspire BioPharma is trading 5.5% up today on broader biotech sector rally
Aspire BioPharma is trading 5.5% up today at $7.43, rebounding after yesterdayβs profit-taking pullback. β’ The move aligns with a broader biotech rally and...